BioPharmX adds board member
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
BioPharmX Corp.'s board elected Charles Vontz as an independent board member, effective Jan. 17.
Vontz was most recently the president and CEO of Topica Pharmaceuticals.
The company's board now comprises four directors, three of whom are independent.